• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
ATRA

ATRA

Atara Biotherapeutics, Inc.

NASDAQHealthcareBiotechnologyUS

USD9.63

-0.27 (-2.73%)

Rating:C

Company Profile

CEO

Anhco Nguyen

IPO Date

2014-10-16

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$10.03

Prev. Close

$9.90

Day Low

$9.36

Day High

$10.23

52W Low

$3.92

52W High

$19.14

Market Cap

$0.09B

Volume

0.10M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

29.0%

Avg Negative

3.0%

Avg Neutral

68.0%

News Feed

Atara Biotherapeutics, Inc. (ATRA) CEO Pascal Touchon on Q2 2021 Results - Earnings Call Transcript

Seeking Alpha·8/9/2021·↓ negative

Atara Biotherapeutics (ATRA) Reports Q2 Loss, Misses Revenue Estimates

Zacks Investment Research·8/9/2021·↑ positive

Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire·8/2/2021·↑ positive

Atara Biotherapeutics: Upcoming Catalysts And Validated Pipeline

Seeking Alpha·6/30/2021·↑ positive

Atara Biotherapeutics Presents Positive Tab-cel® Long-Term Overall Survival Data for Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease After Solid Organ Transplant at ATC 2021 Virtual Connect

Business Wire·6/7/2021·↑ positive

Atara Biotherapeutics' (ATRA) CEO Pascal Touchon on Q1 2021 Results - Earnings Call Transcript

Seeking Alpha·5/5/2021·↓ negative

Atara Biotherapeutics (ATRA) Reports Q1 Loss, Lags Revenue Estimates

Zacks Investment Research·5/4/2021·↑ positive

Atara Biotherapeutics to Announce First Quarter 2021 Financial Results on Tuesday, May 4, 2021

Business Wire·4/27/2021·↑ positive

Atara Biotherapeutics Presents New Long-Term Overall Survival Data from a Combined Analysis of Phase 2 Tab-cel® Studies for Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease at The EBMT 2021 Annual Meeting

Business Wire·3/14/2021·↑ positive

Atara Biotherapeutics, Inc. (ATRA) CEO Pascal Touchon on Q4 2020 Results - Earnings Call Transcript

Seeking Alpha·3/1/2021·↓ negative